Fresenius Taps China’s WuXi to Expand Biosimilar Drug Portfolio

Fresenius SE agreed to partner with Chinese contract drug developer WuXi Biologics on biosimilar candidates that could reach the market in the next decade, potentially more than doubling its current portfolio.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.